Topics

The RNA Horizons 2027 Conference will cover a broad range of topics including:

• AI, Foundation Models & Computational RNA Biology
  RNA foundation models, generative AI, computational RNA design, prediction of RNA structure and function, RNA–protein interactions, multimodal AI, AI-driven biomarker discovery and AI-assisted therapeutic development.
• RNA Splicing, Processing & Regulation
  Alternative splicing, RNA-binding proteins, RNA processing, RNA stability and degradation, and post-transcriptional regulation.
• Next-Generation Transcriptomics: Long-Read, Single-Cell, Spatial & Multi-Omics
  Long-read and direct RNA sequencing, transcript isoform discovery, single-cell RNA sequencing, spatial transcriptomics, cellular heterogeneity and integrated multi-omics, including AI-enabled analysis of complex transcriptomic datasets.
• RNA Editing, Epitranscriptomics & Frontiers in RNA Biology
  RNA editing, RNA modifications, epitranscriptomics, emerging RNA mechanisms and major new discoveries in RNA biology.
• RNA Therapeutics, Engineering & Delivery
  mRNA therapeutics, ASOs, siRNA, RNA engineering, RNA editing technologies, delivery platforms, nanoparticles, tissue- and cell-specific targeting, and AI-assisted therapeutic design.
• RNA in Cancer, Immunology & Precision Medicine
  RNA-based cancer therapies, cancer vaccines, immune modulation, biomarkers, patient stratification, precision oncology and AI-supported patient selection and biomarker development.
• RNA in Rare Diseases & Beyond Oncology
  Rare and genetic diseases, neurological, cardiovascular and metabolic diseases, regenerative medicine and other expanding applications of RNA therapeutics.
• Clinical Translation & RNA Drug Development
  The path from discovery to patients: preclinical development, clinical trials, safety, manufacturing, regulation, translational bottlenecks, patient stratification and lessons from clinical development.
• Industry Innovation, AI & the Future of RNA Medicine
  Biotech and pharma perspectives, AI-enabled drug discovery, emerging technology platforms, commercialization, partnerships, investment and the technologies expected to shape the next generation of RNA medicines.